Is Anthem Biosciences a Good Buy After Its Q1 FY27 Results?

September 8, 2026
Posted by: Kunal Singla
Category: Market

Anthem Biosciences share price around Rs 925. 5.0% below 52-week high of Rs 974. Q1 FY27 revenue Rs 443 crore, down 21.3% YoY. PAT Rs 120 crore, down 11.7%. PE 91x.

Quick Answer

Anthem Biosciences’ Q1 FY27 results were mixed, with revenue at Rs 443 crore but PAT falling 12% to Rs 120 crore. The Anthem Biosciences share price near Rs 925 has not escaped this pressure, and the profit decline is the key data point investors should weigh before deciding whether Anthem Biosciences is a good buy right now.

The Anthem Biosciences share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Anthem Biosciences is a contract research, development and manufacturing organisation (CRDMO) for pharma and biotech clients, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 443 crore, down 21.3% year on year, while profit after tax came in at Rs 120 crore, down 11.7% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Anthem Biosciences share price from here.

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Anthem Biosciences share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Table of Contents

Anthem Biosciences Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 443 crore	Rs 563 crore	-21.3%
EBITDA	Rs 175 crore	Rs 214 crore	-18.1%
Operating Margin	42.0%	39.7%	NA
Profit Before Tax	Rs 145 crore	Rs 186 crore	-22.4%
Net Profit / (Loss)	Rs 120 crore	Rs 136 crore	-11.7%

Anthem Biosciences Q1 FY27 Performance Analysis

Check Anthem Biosciences Fundamentals on Univest Screener

Revenue declined 21.3% for the quarter, which was not offset by cost control, and the pharmaceutical contract research and manufacturing (CRDMO) business will need a stronger showing next quarter to reverse the trend.

Profitability is where the quarter disappointed. PAT fell 12% year on year to Rs 120 crore with revenue also down 21.3%, which points to margin or cost pressure that management will need to address. This gap between top-line and bottom-line performance is the key thing weighing on the Anthem Biosciences share price this quarter.

On a sequential basis, revenue moved down 33.1% sequentially from Rs 662 crore in the March 2026 quarter and net profit moved down 36.8% sequentially from Rs 190 crore in the prior quarter, giving a fuller picture of the trend behind the Anthem Biosciences share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Anthem Biosciences’ revenue declined 21.3% year on year this quarter, taking the quarterly base to Rs 443 crore in a pharmaceutical contract research and manufacturing (CRDMO) business that remains sensitive to demand and pricing cycles that ultimately feed through to the Anthem Biosciences share price.

Margin Movement

EBITDA fell to Rs 175 crore from Rs 214 crore, with operating margin slipping to 42.0% from 39.7%, pointing to cost or pricing pressure that management will need to manage through the rest of FY27.

Balance Sheet Position

Anthem Biosciences carries a low debt-to-equity ratio of 0.02, giving it a conservative balance sheet heading into the rest of FY27.

Valuation Context

The stock trades at a PE of 91.4x against an industry average of 37.7x, a premium that this quarter’s results will need to justify going forward.

Dividend Details

No interim dividend was declared alongside Anthem Biosciences’ Q1 FY27 results. The stock currently carries a trailing dividend yield of 0.21%, based on dividends paid over the last year. Investors tracking the Anthem Biosciences share price for income should watch the company’s announcements around its next annual results for any dividend decision.

Anthem Biosciences Share Price Outlook for FY27

The key question for the rest of FY27 is whether Anthem Biosciences can arrest the margin pressure seen this quarter. Revenue growth alone will not be enough to support the Anthem Biosciences share price if profitability keeps slipping, so investors should watch the next couple of quarters for signs of a turnaround in the bottom line.

A stabilising or improving margin trend in the next result would be the clearest signal that this quarter’s profit decline was a temporary setback rather than the start of a longer slide for the Anthem Biosciences share price.

Anthem Biosciences Stock Performance

Download the Univest iOS App or Univest Android App to track Anthem Biosciences’ live share price and get daily stock updates.

The Anthem Biosciences share price was trading around Rs 925 as results season played out in late August 2026, roughly 5.0% below its 52-week high of Rs 974 and well above its 52-week low of Rs 579. Promoter holding stood at 71.4% as of the June 2026 quarter.

The Anthem Biosciences share price has likely already absorbed some of this quarter’s disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of 19.45% and a book value of around Rs 54 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Valuation Risk

At 91.4x earnings against an industry average of 37.7x, the stock leaves little room for disappointment if growth slows.

Profitability Risk

The quarter’s profit trend is the clearest risk here. Until Anthem Biosciences shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.

Sector and Demand Risk

As a pharmaceutical contract research and manufacturing (CRDMO) business, Anthem Biosciences’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Anthem Biosciences share price well before the next result.

Conclusion

Anthem Biosciences’ Q1 FY27 results were weak on both counts, with PAT down 12% to Rs 120 crore, with revenue also falling 21.3%. The Anthem Biosciences share price reflects a stock in wait-and-watch mode, and it is not an obvious buy purely on this quarter’s numbers until both the topline and margin trend turn around.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Anthem Biosciences Q1 FY27 Results

What were Anthem Biosciences’ Q1 FY27 results?

Ans. Anthem Biosciences reported Q1 FY27 revenue of Rs 443 crore, down 21.3% year on year, and PAT of Rs 120 crore, down 11.7% year on year.

Is Anthem Biosciences a good buy after its Q1 FY27 results?

Ans. Anthem Biosciences’ profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.

What is the Anthem Biosciences share price today?

Ans. The Anthem Biosciences share price was trading around Rs 925 in late August 2026, about 5.0% below its 52-week high of Rs 974 and well above its 52-week low of Rs 579.

What is Anthem Biosciences’ revenue and profit for Q1 FY27?

Ans. Anthem Biosciences reported revenue of Rs 443 crore and a net profit of Rs 120 crore for the quarter ended June 30, 2026.

Did Anthem Biosciences declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Anthem Biosciences’ Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.

What is Anthem Biosciences’ PE ratio and is it expensive?

Ans. The Anthem Biosciences share price trades at a trailing PE of 91.4x, against an industry average of 37.7x. Investors should compare this with the company’s growth rate before judging value.

What are the key risks for Anthem Biosciences investors right now?

Ans. At 91.4x earnings against an industry average of 37.7x, the stock leaves little room for disappointment if growth slows. As a pharmaceutical contract research and manufacturing (CRDMO) business, Anthem Biosciences’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Anthem Biosciences share price well before the next result.

What is Anthem Biosciences’ promoter shareholding?

Ans. Promoter holding in Anthem Biosciences stood at 71.4% as of the June 2026 quarter.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.